Screener
Vaxcyte, Inc. PCVX Business Segments — G&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Operating expenses: | | | | Research and development - external costs (1) | $256,432 | $103,806 | | Research and development - internal costs (2) | 56,347 | 44,328 | | General and administrative | 33,071 | 32,659 | | Total operating expenses | $345,850 | $180,793 | | Total other income, net | 25,228 | 40,075 | | Net loss | $320,622 | $140,718 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s business segments — G&A?
- Vaxcyte, Inc. (PCVX) reported business segments — G&A of $33.07M in Q1 2026.
- How has Vaxcyte, Inc.'s business segments — G&A changed year-over-year?
- Vaxcyte, Inc.'s business segments — G&A increased by 1.3% year-over-year, from $32.66M to $33.07M.
- What is the long-term trend for Vaxcyte, Inc.'s business segments — G&A?
- Over 3 years (2022 to 2025), Vaxcyte, Inc.'s business segments — G&A has grown at a 48.1% compound annual growth rate (CAGR), from $39.81M to $129.37M.
- What does business segments — G&A mean?
- This metric captures the overhead costs associated with the daily operations of the business segment, including executive compensation, legal, finance, and other corporate support functions. It serves as a measure of the operational efficiency and administrative burden required to sustain the segment's activities. Monitoring this helps assess the scalability of the organization's infrastructure.
Ask your AI about Vaxcyte, Inc.'s business segments — g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude